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Introduction
Status epilepticus represents an acute neurological condition with considerable morbidity and an estimated short-term mortality of up to 22% 1, 2 . Several studies have shown that outcome is independently related to increasing age, underlying etiology, and SE severity [3] [4] [5] [6] , while the specific impact of antiepileptic treatment is debated 7 . Moreover, the role of medications not related to seizure suppression has received scarce attention so far.
Statins are competitive inhibitors of 3-hydroxy-3-methylglutaryl co-enzyme A (HMG-CoA)
reductase, the key enzyme in cholesterol biosynthesis. They are usually prescribed in hypercholesterolemia, atherosclerosis diseases, and for secondary prevention of cardiovascular disease [8] [9] [10] . Recently, statins potential neuroprotective, anti-inflammatory and antiexcitotoxic effects have been described in animal models of different neurological processes, such as multiple sclerosis, Parkinson's and Alzheimer's diseases, traumatic brain injury (TBI), and, particularly, epilepsy [11] [12] [13] [14] [15] , where these compounds seem to decrease seizures severity and related hippocampal cell death in rodent models [16] [17] [18] [19] .
Despite the wide prescription of statins, their potential effect in human epilepsy has been addressed in only two observational studies, which showed a protective role for the risk of developing epilepsy in elderly patients 20, 21 . Nevertheless, to the best of our knowledge, their role in status epilepticus (SE) prognosis in humans has not been studied so far. The present analysis was designed to investigate the relationship of statins with SE outcome.
PATIENTS AND METHODS

Patients
This observational cohort study enrolled consecutive adults with an incident episode of SE, treated at our tertiary care center between April 1, 2006 and September 1, 2012 (77 months) and prospectively included in our registry 22 . Subjects younger than 16 years, with post-anoxic SE, or with previous SE episodes were excluded. We retrospectively collected information (assessed through charts review) regarding different types and doses of statins administered on a daily basis before admission for the incident SE episode. This study was fully approved by the research ethics committee of the Canton of Vaud.
Definition of variables
As detailed previously 22 
Procedures
All subjects underwent electrolytic, metabolic, and hematologic work-up. Brain imaging supression for at least 24 h before weaning the anesthetic medication over 12-24 h. In these cases, propofol, midazolam, and thiopental were used alone or in combination.
Statistical analyses
Data analysis was performed using STATA 12.1 (College Station, TX, USA). Data were summarized as mean (±sd) for continuous variables and as numbers (percentages) for categorical data. Univariate multinomial logistic regression was performed to assess the association of potential outcome predictors (age, gender, SE semiology, occurrence of previous seizures, potentially fatal etiology, STESS, SE duration shorter than 30 minutes, and previous statins treatment) to the SE outcome. The strength of the associations was measured using the RRR (Relative Risk Ratio), where the ''return to baseline'' group was fixed as the reference.
Significant predictors at the level of 20% were used in a backward procedure to fit a multivariate model.
RESULTS
From a total of 515 SE episodes recorded during the study period, we identified 427 incident patients. In 413 of them (80% of total, 97% of the incident episodes), data regarding statin treatment on admission were available: mean age was 60. (5%) nonconvulsive SE in coma. Statins (simvastatin, atorvastatin and pravastatin) were prescribed before admission in 76 (18%) subjects. For details, see Figure 1 . Regarding SE outcome, 208 (50%) patients returned to baseline clinical conditions, whereas 58 (14%) died. Table 2) . Older age and potentially fatal etiology were independent predictors for both outcomes, while previous seizures were only related to a lower risk of new disability. A high STESS score was independently related to a higher mortality, but it was not associated to a lower disability. Of note, there was no interaction between statins and stroke as regards SE outcome. Figure 2 illustrates that the association between age and mortality after a first episode of SE was maintained in patients exposed to statins, however at a lower occurrence rate.
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DISCUSSION
This study provides Class III evidence that statins, usually prescribed for reducing cardiovascular risk, are significantly correlated with a lower risk of mortality after SE, following adjustment for the most important outcome predictors [3] [4] [5] 24 .
Only two human studies have examined the possible benefits of HMG-CoA inhibitors in modifying the risk of epilepsy so far. The rate of new-onset epilepsy in older veterans was lowered by statin prescription (OR 0.64, 95% CI 0.56-0.73), suggesting a possible target for prevention of geriatric epilepsy 20 . Among a large cohort of cardiovascular patients who received a revascularization procedure, 217 cases with a diagnosis of epilepsy were matched to 2170 controls by age and admission time; the adjusted risk ratio for epilepsy among statin users was 0.65 (95% CI 0.46-0.92), whereas no benefit was found for non-statin cholesterol-lowering drugs, β-blockers, or angiotensin-converting enzyme inhibitors 21 . Overall, these two congruent findings suggest a protective effect of statins for the risk of developing epilepsy. Our results therefore expand these observations in adults with incident SE. Statins use was only related to mortality but not to new disability: mortality after SE mostly relates to etiology and complications, and not to SE itself [3] [4] [5] , it is therefore possible that statines also impacted on the the global health of acutely admitted patients. Furthermore, disability is not as a robust outcome as mortality, and is assessed at a variable time (hospital discharge), likely influencing the strengths of the found relationships.
Several experimental studies have supported the antiepileptogenic properties of statins.
Simvastatin, lovastatin and atorvastatin reduced the severity of kainite-induced-seizures and excitotoxicity in the hippocampus and limbic structures 16, 17 , and atorvastatin also attenuated kainate-induced hippocampal cellular death involving the Akt-phosphorylation pathway and glutamate transport modulation 18 . An additive anticonvulsant effect of simvastatin, fluvastatin, lovastatin and atorvastatin, when co-administered with some antiepileptic compounds in the DBA/2 mice model of generalized tonic-clonic seizure has been reported 19 . Our findings suggest a possible anti-epileptogenic mechanism of statins also in humans, which might be the consequence of anti-inflammatory properties 26, 27 , in light of the increasing evidence of a link between inflammation and the epileptogenicity [28] [29] [30] .
This study has some limitations. Although our SE database is prospective, ensuring the best possible data quality for variables assessed acutely, data collection regarding previous statin treatment was retrospective; however, we were able to find detailed information for the vast majority of patients. The predictive models were not adjusted for medical comorbidities, although these show only a marginal added value in outcome prognostication 24 . Indeed, our statistical model controlled for potential confounding by the most robust prognostic factors. We did not analyzed antiepileptic treatment, since on a subgroup of patients of the present cohort we recently showed that treatment appropriateness does not significantly influence clinical outcome 7 . Finally, statins were not analyzed separately regarding type and dose, due to the relatively low numbers in each group. Conversely, this study includes a large number of patients with SE diagnosis, and to the best of our knowledge it is the first addressing this question. Further studies are needed to confirm this potentially important clinical observation.
12 Sierra-Marcos et al. 
TABLES:
